Seres Therapeutics Inc’s (NASDAQ: MCRB) Stock Price Will Be Bearish Or Bullish In 2024

Seres Therapeutics Inc (NASDAQ:MCRB) shares, rose in value, with the stock price down by -4.88% to the previous day’s close as strong demand from buyers drove the stock to $0.73.

Actively observing the price movement in the last trading, the stock closed the session at $0.76. The value of beta (5-year monthly) was 2.27. Referring to stock’s 52-week performance, its high was $6.87, and the low was $0.73. On the whole, MCRB has fluctuated by -36.35% over the past month.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

With the market capitalization of Seres Therapeutics Inc currently standing at about $109.57 million, investors are eagerly awaiting this quarter’s results, scheduled for May 07, 2024 – May 13, 2024. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.34, which is expected to increase to -$0.2 for fiscal year -$1.14 and then to about -$0.8 by fiscal year 2025. Data indicates that the EPS growth is expected to be -28.10% in 2025, while the next year’s EPS growth is forecast to be 29.80%.

According to the average forecast, sales growth in current quarter could jump down -81.90%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2025, the company’s y-o-y revenues would reach $1.36 million, representing a decrease of -98.90% from the revenues reported in the last year’s results.

Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that MCRB’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium term indicators have put the stock in the category of 100% Sell while long term indicators on average have been pointing out that it is a 100% Sell.

The stock’s technical analysis shows that the PEG ratio is about 0, with the price of MCRB currently trading nearly -12.37% and -27.75% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 33.16, while the 7-day volatility ratio is showing 5.92% which for the 30-day chart, stands at 8.10%. Furthermore, Seres Therapeutics Inc (MCRB)’s beta value is 2.25, and its average true range (ATR) is 0.07.

A comparison of Seres Therapeutics Inc (MCRB) with its peers suggests the former has fared considerably weaker in the market. MCRB showed an intraday change of -4.88% in last session, and over the past year, it shrunk by -87.20%%.

Data on historical trading for Seres Therapeutics Inc (NASDAQ:MCRB) indicates that the trading volumes over the past 10 days have averaged 3.08 million and over the past 3 months, they’ve averaged 4.65 million. According to company’s latest data on outstanding shares, there are 135.04 million shares outstanding.

Nearly 24.42% of Seres Therapeutics Inc’s shares belong to company insiders and institutional investors own 44.23% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 18.4 million shares as on Mar 15, 2024, resulting in a short ratio of 3.79. According to the data, the short interest in Seres Therapeutics Inc (MCRB) stood at 12.18% of shares outstanding as of Mar 15, 2024; the number of short shares registered in Feb 15, 2024 reached 15.59 million. The stock has fallen by -48.17% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the MCRB stock heading into the next quarter.